Literature DB >> 16409565

Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times.

S G Ashwell1, J Gebbie, P D Home.   

Abstract

AIMS: To compare blood glucose control when insulin glargine is given at lunch-time, dinner-time, and bed-time in people with Type 1 diabetes using insulin lispro at meal-times.
METHODS: In this 16-week, three-way, cross-over study, 23 people with Type 1 diabetes were randomized to insulin glargine injection at lunch-time (L) [mean 12.37 +/- 00.34 (+/- sd) h], dinner-time (D) (18.12 +/- 00.40 h), or bed-time (B) (22.29 +/- 00.40 h), each plus meal-time insulin lispro. Each 4-week treatment period concluded with a 24-h inpatient metabolic profile.
RESULTS: Insulin doses, HbA(1c), and fructosamine concentration did not differ between treatment periods. Pre-breakfast self-monitored blood glucose (SMBG) concentration was higher with injection of glargine at lunch-time than at other times [L: 9.2 +/- 0.3 (+/- se) vs. D: 8.2 +/- 0.3 or B: 8.0 +/- 0.3 mmol/l, P = 0.016], as probably was pre-lunch SMBG (L: 8.6 +/- 0.7 vs. D: 6.4 +/- 0.7 or B: 6.4 +/- 0.8 mmol/l, P = 0.051). Pre-dinner SMBG level was higher with dinner-time glargine than other injection times (D: 9.4 +/- 0.9 vs. L: 4.9 +/- 0.9 or B: 7.4 +/- 1.1 mmol/l, P = 0.007). For 22.00 to 02.00 h, mean inpatient plasma glucose concentration was higher with injection of glargine at bed-time than other times (B: 9.1 +/- 0.6 vs. L: 7.8 +/- 0.6 or D: 6.7 +/- 0.6 mmol/l, P = 0.023). Plasma free insulin concentration was lower at the end of the afternoon with dinner-time glargine than other injection times (D: 11.5 +/- 1.4 vs. L: 20.2 +/- 1.3 or B: 16.5 +/- 1.3 mU/l, P < 0.001). Frequency of hypoglycaemia was not different, but timing of hypoglycaemia differed between treatment periods.
CONCLUSIONS: Blood glucose levels rise around the time of injection of insulin glargine whether given at lunch-time, dinner-time or bed-time. Bed-time injection leads to hyperglycaemia in the early part of the night which is improved by giving insulin glargine at lunch-time or dinner-time.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16409565     DOI: 10.1111/j.1464-5491.2005.01726.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  12 in total

Review 1.  Insulin analogues in type 1 diabetes mellitus: getting better all the time.

Authors:  Chantal Mathieu; Pieter Gillard; Katrien Benhalima
Journal:  Nat Rev Endocrinol       Date:  2017-04-21       Impact factor: 43.330

Review 2.  Clinical experience with insulin glargine in type 1 diabetes.

Authors:  Satish Garg; Emily Moser; Marie-Paule Dain; Anastasia Rodionova
Journal:  Diabetes Technol Ther       Date:  2010-10-22       Impact factor: 6.118

3.  Comment on: Distiller LA, Joffe BI (2006) From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a 'routine' diabetes clinic? Diabetologia 49:2793-2794.

Authors:  D S H Bell
Journal:  Diabetologia       Date:  2007-01-18       Impact factor: 10.122

4.  The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back.

Authors:  S G H A Swinnen; F Holleman; J H DeVries
Journal:  Diabetologia       Date:  2008-08-01       Impact factor: 10.122

Review 5.  New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations.

Authors:  Paris Roach
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 6.  Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised?

Authors:  David S H Bell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value.

Authors:  Rhian Clissold; Steve Clissold
Journal:  Core Evid       Date:  2007-11-30

Review 8.  Circadian Variation in Efficacy of Medications.

Authors:  James C Walton; William H Walker; Jacob R Bumgarner; O Hecmarie Meléndez-Fernández; Jennifer A Liu; Heather L Hughes; Alexis L Kaper; Randy J Nelson
Journal:  Clin Pharmacol Ther       Date:  2020-11-29       Impact factor: 6.903

Review 9.  The evolution of insulin glargine and its continuing contribution to diabetes care.

Authors:  Rolf Hilgenfeld; Gerhard Seipke; Harald Berchtold; David R Owens
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

10.  Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).

Authors:  Jean-Pierre Le Floch; Marc Lévy; Helen Mosnier-Pudar; Frank Nobels; Sylvie Laroche; Sophie Gonbert; Eveline Eschwege; Pierre Fontaine
Journal:  Diabetes Care       Date:  2008-10-22       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.